Analysis of HCV-immunoglobulin isotype complexes provide new insights into antibody response to HCV

Scandinavian Journal of Immunology

Volumn 56, Issue 1, 2002, Pages 94-100

  Peng, X X ^a   Wang, S Y ^a   Zhang, J Y ^a   Zhu, H ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SUPERNATANT; VIREMIA; VIRION; VIRUS MUTATION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIGEN-ANTIBODY COMPLEX; BASE SEQUENCE; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULIN ISOTYPES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTAGENESIS; RNA, VIRAL;

EID: 0036422958     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2002.01112.x     Document Type: Article

References (26)

1. Bartenschlager R. Molecular targets in inhibition of hepatitis C virus replication. Antivir Chem Chemother 1997;8:281-301.
2. Papatheodoridis GV, Delladetsima JK, Katsoulidou A et al. Significance of IgM anti-HCV core level in chronic hepatitis C. J Hepatol 1997;27:36-41.
3. Arthur RR, Hassan NF, Abdallah MY et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997;91:271-4.
4. Tanaka M, Sato S, Fujiyama S et al. Clinical study of IgA antibody against hepatitis C virus core antigen in patients with types C chronic liver disease. Dig Dis Sci 1995;40:457-64.
5. Noguchi S, Sata M, Suzuki H, Mizokami M, Tanikawa K. Routes of transmission of hepatitis C virus in an endemic rural area of Japan - Molecular epidemiologic study of hepatitis C virus infection. Scand J Infect Dis 1997;29:23-8.
6. Choo SH, So HS, Cho JM, Ryu WS. Association of hepatitis C virus particles with immunoglobulin: A mechanism for persistent infection. J Gen Virol 1995;76:2337-41.
7. Hijikata M, Shimizu YK, Kato H et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J Virol 1993;67:1953-8.
8. Kanto T, Hayashi N, Takehara T et al. Buoyant density of hepatitis C virus recovered from infected hosts: Two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatol 1994;19: 296-301.
9. Peng XX, Zhu H, Zhang JY, Wang SY. Analysis of HCV-Ig isotype complexes by a novel immuno-capture RT-PCR method. Scand J Immunol 2001;4:409-13.
10. Hongyo T, Buzard GS, Palli D et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence. Italy Cancer Res 1995;55:2665-72.
11. Cairns M J, Murry V. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotech 1994;17:209-14.
12. Cerino A, Meola A, Segagni L et al. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J Immunol 2001;167:3878-86.
13. Sandres K, Dubois M, Pasquier C, Puel J, Izopet J. Determination of HCV genotype using two antibody assays and genome typing. Eur J Clin Microbiol Infect Dis 2001;20:666-9.
14. Takamizawa A, Mori C, Fuke I et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65:1105-13.
15. Choo QL, Kuo G, Weiner A J, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A non-B hepatitis genome. Science 1989;21:359-62.
16. Harmatz PR, Kleinman RE, Bunnell BW, McClenathan DT, Walker WA, Bloch KJ. The effect of bile duct obstruction on the clearance of circulating IgA immune complexes. Hepatol 1984;4:96-100.
17. Peppard J, Orlans E, Payne AW, Andrew E. The elimination of circulating complexes containing polymeric IgA by excretion in the bile. Immunology 1981;42:83-9.
18. Rosenberg S, Tarre H. Tracking and treating Hepatitis C infection. Business Health 1999;17:41-2.
19. Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshioka K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:468-72.
20. Hino K, Yamaguchi Y, Fujiwara D et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: A prospective study. J Viral Hepatitis 2000;7:36-42.
21. Doughty AL, Painter DM, McCaughan GW. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 2000;32:126-34.
22. Kato T, Mizokami M, Nakano T. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus. J Med Virol 1998;55:109-17.
23. Gonzalez PRP, Liu WZ, Davis GL. Modulation of hepatitis C virus quasispecies heterogeneity by interferon alpha and ribavirin therapy. J Viral Hepatitis 1997;4:99-106.
24. Le GB, Squadrito G, Nalpas B, Hepatitis C. virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C. Hepatol 1997;25:1250-4.
25. Lareu RR, Swanson NR, Fox SA. Rapid and sensitive genotyping of hepatitis C virus by single-strand conformation polymorphism. J Virol Meth 1997;64:11-8.
26. Yuri N, Hayashi N, Moribe T et al. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatol 1997;25:439-44.